Completed PHASE1 INTERVENTIONAL 1-arm NCT01713036

Oral Bioavailability and Mass Balance Trial With Pimasertib

A Phase I, Open-Label, Single Center Trial to Investigate the Mass Balance, Metabolite Profile and Oral Bioavailability of Pimasertib in Cancer Patients With Locally Advanced or Metastatic Solid Tumors

Sponsor: Merck KGaA, Darmstadt, Germany

Conditions Locally Advanced or Metastatic Solid Tumors

Interventions Pimasertib

Updated 7 times since 2017 Last updated: Jul 6, 2017 Started: Nov 30, 2012 Primary completion: Jul 31, 2014 Completion: Jul 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Locally Advanced or Metastatic Solid Tumors and is currently completed. Merck KGaA, Darmstadt, Germany leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2019 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Jan 2019 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Sep 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Sep 2017 [monthly]

Completed PHASE1

First recorded

Nov 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck KGaA, Darmstadt, Germany

Data source: Merck KGaA, Darmstadt, Germany

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Budapest, Hungary